Scholar Rock Holding Corporation Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for SRRK, updated each market day.
SRRK AI Sentiment
AI sees no strong directional signal for Scholar Rock Holding Corporation Common Stock stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Scholar Rock Holding Corporation Common Stock
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Sector
Exchange
Market Cap
$5,664,453,547
Cap Tier
Employees
289
Headquarters
CAMBRIDGE, MA
Listed Since
May 24, 2018
Website
SRRK Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
SRRK Volatility
Scholar Rock Holding Corporation Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
